UPDATE 1-Pfizer's Herceptin biosimilar succeeds in key breast cancer study
November 30, 2016 at 09:33 AM EST
Nov 30 (Reuters) - Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study.
